Email bulletin archive

Archive

December 2018

• Global trends in non-alcoholic fatty liver disease
• NAFLD can occur in lean people too
• Hepatitis C and the US opioid epidemic
• Resistance testing for hepatitis C
• Rwanda aims for hepatitis C elimination
• Egypt hepatitis C elimination
• Is this your copy of the infohep news bulletin?

November 2018

• News from The Liver Meeting
• Aspirin reduces liver cancer risk
• Sofosbuvir/ledipasvir for children aged three to six years
• Hepatitis C in rectal and nasal fluid
• Diabetes, stroke and cancer incidence fall after hepatitis C cure
• 8-week Maviret in cirrhosis
• NAFLD and cancer risk
• Experimental treatments for NASH and NAFLD
• Nivolumab for liver cancer
• HCV treatment in people who inject drugs
• Glecaprevir/pibrentasvir licensed to the Medicines Patent Pool
• Is this your copy of the infohep news bulletin?

October 2018

• Microelimination of HCV in people with co-infection
• Testing for hepatitis C
• What support do people with liver cirrhosis and their families need?
• What are the barriers to hepatitis C treatment in prisons?
• Low dead-space syringes associated with lower HCV prevalence
• Need for liver transplants due to hepatitis C drops in the United Kingdom
• News coverage of The Liver Meeting 2018
• Is this your copy of the infohep news bulletin?

September 2018

• DAA treatment highly effective for people who use drugs
• HCV elimination in people who inject drugs
• Little progress towards universal testing of 'baby boomer' generation in United States
• Reinfection risk higher in recent drug users
• Screening pregnant women and infants for hepatitis C
• Psychological relief is the most important benefit of being cured of hepatitis C, say patients
• Safety and effectiveness of DAAs in older people
• Is this your copy of the infohep news bulletin?

August 2018

• End-stage liver disease deaths due to hepatitis C fall in the United Kingdom and Australia
• Supervised drug consumption rooms and hepatitis C testing and treatment
• Injecting drug users in South Africa: a high prevalence of HCV
• Transplants using organs from donors with HCV
• China Gilead patent
• Zepatier price cut
• Is this your copy of the infohep news bulletin?

July 2018

• World Hepatitis Day
• Treat all with hepatitis C, World Health Organization recommends
• Identifying people in need of hepatitis B treatment in Africa
• Hepatitis C treatment for people without liver damage
• Improved survival after liver transplant
• Access to HCV treatment for people with substance use or mental health issues
• Ramucirumab for liver cancer
• Is this your copy of the infohep news bulletin?

June 2018

• Hepatitis C testing and treatment in prisons
• Scotland and harm reduction
• Hepatitis C treatment and payer coverage in US
• Birth cohort testing in Canada
• Hepatitis C testing in community pharmacies
• Hepatitis C drugs to be discontinued
• Treatment for NASH
• 7th International Symposium on Hepatitis Care in Substance Users
• 2nd HEP-C Community Summit
• Is this your copy of the infohep news bulletin?

May 2018

• Quality of life after hepatitis C cure
• Portal hypertension after hepatitis C cure
• Cardiovascular disease risk and sustained virologic response
• Myrcludex: treatment for hepatitis delta
• Tenofovir alafenamide as treatment for hepatitis B
• Experimental treatment for hepatitis B
• Hepatitis C elimination in Georgia
• Treatment for hepatitis C in Africa
• Is this your copy of the infohep news bulletin?

April 2018

• News from the 2018 International Liver Congress, Paris
• Effectiveness of hepatitis C treatment
• EASL HCV treatment guidelines
• Liver cancer treatment guidelines
• Liver cancer treatment
• Liver cancer risk after DAA treatment
• Access to treatment
• Cost-effectiveness of early treatment for hepatitis C
• Shorter treatment courses for genotype 3
• Is this your copy of the infohep news bulletin?

March 2018

• WHO progress report on access to treatment
• Hepatitis B: five countries account for more than half of all HBV infections
• Prevention of mother-to-child transmission of hepatitis B
• Hepatitis C elimination in prisoners
• Eliminating hepatitis C in England
• Successful HCV therapy reduces the risk of diabetes
• Next month: News from The International Liver Congress
• Is this your copy of the infohep news bulletin?

February 2018

• Harm reduction scale-up needed to reduce HCV prevalence among people who inject drugs
• Slowdown in new treatment uptake for hepatitis C starts in Australia
• Hepatitis C elimination in Georgia
• Improvement in fibrosis after hepatitis C cure
• Smoking in people with hepatitis C
• Is this your copy of the infohep news bulletin?

January 2018

• NHS England aims for hepatitis C elimination by 2025
• Hepatitis B and secondary liver cancer
• Smoking and survival after liver cancer diagnosis
• Real world data on treatment success in people with HIV/HCV co-infection
• Is this your copy of the infohep news bulletin?